Search Results

Return to List
Results 21–39 of 39
Title Date
21.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT: In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatme...

June 2014

PDF Format
22.

Optimal Goals for Anesthesia Care in Obstetrics

Number 433

(Replaces No. 256, May 2001)

ABSTRACT: A joint statement from the American Society of Anesthesiologists and the American College of Obstetricians and Gynecologists was developed to address issues of concern to both specialties. ...

May 2009

PDF Format
23.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT: Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding, and gynecologists may be consulted either before the initiation of cancer treatment to request strategi...

August 2014

PDF Format
24.

Over-the-Counter Access to Oral Contraceptives

Number 544

ABSTRACT: Unintended pregnancy remains a major public health problem in the United States. Access and cost issues are common reasons why women either do not use contraception or have gaps in use. A p...

December 2012

PDF Format
25.

Pain Relief During Labor

Number 295

(Reaffirmed 2008, Replaces No. 231, February 2000)

ABSTRACT: Pain management should be provided whenever medically indicated. The American Society of Anesthesiologists (ASA) and the American College of Obstetricians and Gynecologists (ACOG) believe t...

July 2004

PDF Format
26.

Patents Medicine and the Interests of Patients

Number 364

(Reaffirmed 2009)

ABSTRACT: Many basic scientists and clinicians support the right to obtain and enforce patents on drugs, diagnostic tests, medical devices, and most recently, genes. Although those who develop useful...

May 2007

PDF Format
27.

Pharmacogenetics

Number 488

ABSTRACT: Pharmacogenetics is the study of genetic variations in drug response that are determined by specific genes. It is hoped that the use of pharmacogenetics in clinical practice may improve dru...

May 2011

PDF Format
28.

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

ABSTRACT: The development of menopausal symptoms and related disorders, which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy, is a common reason for a patien...

April 2013

PDF Format
29.

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Number 595

Abstract: Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus (HIV) and are at the highest ris...

May 2014

PDF Format
30.

Prevention of Early-Onset Group B Streptococcal Disease in Newborns

Number 485

(Reaffirmed 2013, Replaces No. 279, December 2002)

ABSTRACT: In 2010, the Centers for Disease Control and Prevention revised its guidelines for the prevention of perinatal group B streptococcal disease. Although universal screening at 35–37 weeks of ...

April 2011

PDF Format
31.

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT: Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years. There is no consensus on criteria to identify primary ovaria...

July 2014

PDF Format
32.

Professional Relationships With Industry

Number 541

(Replaces No. 401, March 2008)

ABSTRACT: The American College of Obstetricians and Gynecologists (the College) has a long history of leadership in ensuring that its educational mission is evidence based and unbiased. A predecessor...

November 2012

PDF Format
33.

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested tha...

November 2012

PDF Format
34.

Solutions for Surgical Preparation of the Vagina

Number 571

ABSTRACT: Currently, only povidone-iodine preparations are approved for vaginal surgical-site antisepsis. However, there are compelling reasons to consider chlorhexidine gluconate solutions for off-l...

September 2013

PDF Format
35.

Subclinical Hypothyroidism in Pregnancy

Number 381

(Reaffirmed 2012)

ABSTRACT: Subclinical hypothyroidism is diagnosed in asymptomatic women when the thyroid-stimulating hormone level is elevated and the free thyroxine level is within the reference range. Thyroid horm...

October 2007

PDF Format
36.

Sulfonamides, Nitrofurantoin, and Risk of Birth Defects

Number 494

(Reaffirmed 2013)

Abstract: The evidence regarding an association between the nitrofuran and sulfonamide classes of antibiotics and birth defects is mixed. As with all patients, antibiotics should be prescribed for pr...

June 2011

PDF Format
37.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuva...

June 2014

PDF Format
38.

Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination

Number 566

(Replaces No. 521, March 2012)

ABSTRACT: In the face of dramatic and persistent increases in pertussis disease in the United States, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has...

June 2013

PDF Format
39.

Vitamin D: Screening and Supplementation During Pregnancy

Number 495

ABSTRACT: During pregnancy, severe maternal vitamin D deficiency has been associated with biochemical evidence of disordered skeletal homeostasis, congenital rickets, and fractures in the newborn. At...

July 2011

PDF Format